Highlights
• Vicento Anido, Jr. Ph.D., Chairman and Chief Executive Officer (CEO) at Aerie Pharmaceuticals said the PAS approval for Rhopressa represents another important manufacturing achievement for the company in the year 2020
• Aerie expects to begin shipping Rhopressa to the U.S. in the last quarter of 2020
According to an announcement made by Aerie Pharmaceuticals Inc. that its sterile fill produc....
Tags : Aerie Pharmaceuticals, USFDA, PAS, Rhopressa, Athlone,
comments (0)